Full Text View
Tabular View
No Study Results Posted
Related Studies
A Phase 2 Study to Evaluate the Efficacy and Safety of GS-6624 in Adults With Myelofibrosis
This study is currently recruiting participants.
Verified April 2013 by Gilead Sciences
Study NCT01369498   Information provided by Gilead Sciences

First Received on June 6, 2011.   Last Updated on April 29, 2013   History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Myelofibrosis
Additional conditions recognized in this trial
Primary Myelofibrosis
Thrombocythemia, Essential
Thrombocytosis
More general conditions related to this trial
Blood Coagulation Disorders
Blood Platelet Disorders
Bone Marrow Diseases
Hematologic Diseases
Hemorrhagic Disorders
Myeloproliferative Disorders
Interventions listed in this trial
GS-6624 at 700 mg
GS-6624 at 200 mg
Sponsors listed in this trial
Gilead Sciences


Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services